Pharmacogenetics is the study of genetically determined indivial variations of drug tolerance. The goal is to tailor the drug therapy to have the best therapeutic effect and tolerance.
1. |
Trask B et al. (1993) Fluorescence in situ hybridization mapping of human chromosome 19: cytogenetic band location of 540 cosmids and 70 genes or DNA markers. |
2. |
Yamano S et al. (1990) The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. |
3. |
Wood AW et al. (1974) Genetic variation in coumarin hydroxylase activity in the mouse (Mus musculus). |
4. |
Lush IE et al. (1978) Genetic variation between mice in their metabolism of coumarin and its derivatives. |
5. |
London SJ et al. (1999) Genetic variation of CYP2A6, smoking, and risk of cancer. |
6. |
Oscarson M et al. (1999) Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. |
7. |
Paolini M et al. (1999) Co-carcinogenic effect of beta-carotene. |
8. |
Miyamoto M et al. (1999) CYP2A6 gene deletion reduces susceptibility to lung cancer. |
9. |
Gu DF et al. (2000) The use of long PCR to confirm three common alleles at the CYP2A6 locus and the relationship between genotype and smoking habit. |
10. |
Hoffman SM et al. (2001) Organization, structure and evolution of the CYP2 gene cluster on human chromosome 19. |
11. |
Daigo S et al. (2002) A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur. |
12. |
Oscarson M et al. (2002) Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. |
13. |
Saito S et al. (2003) Catalog of 680 variations among eight cytochrome p450 ( CYP) genes, nine esterase genes, and two other genes in the Japanese population. |
14. |
OMURA T et al. (1964) THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. I. EVIDENCE FOR ITS HEMOPROTEIN NATURE. |
15. |
Gambier N et al. (2005) Association of CYP2A6*1B genetic variant with the amount of smoking in French adults from the Stanislas cohort. |
16. |
Palmer G et al. (1991) Nomenclature Committee of the International Union of Biochemistry (NC-IUB). Nomenclature of electron-transfer proteins. Recommendations 1989. |
17. |
None (1991) Proposed role of drug-metabolizing enzymes: regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions. |
18. |
Mwenifumbo JC et al. (2008) Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. |
19. |
Miles JS et al. (1990) Close linkage of the cytochrome P450IIA gene subfamily (Cyp2a) to Cyp2b and Coh on mouse chromosome 7. |
20. |
None (1979) Multiple forms of inducible drug-metabolizing enzymes: a reasonable mechanism by which any organism can cope with adversity. |
21. |
Matsunaga T et al. (1990) Structure and in vitro transcription of the rat CYP2A1 and CYP2A2 genes and regional localization of the CYP2A gene subfamily on mouse chromosome 7. |
22. |
Miles JS et al. (1989) Close linkage of the human cytochrome P450IIA and P450IIB gene subfamilies: implications for the assignment of substrate specificity. |
23. |
Yamano S et al. (1989) cDNA and deduced amino acid sequences of human P450 IIA3 (CYP2A3). |
24. |
Negishi M et al. (1989) Mouse steroid 15 alpha-hydroxylase gene family: identification of type II P-450(15)alpha as coumarin 7-hydroxylase. |
25. |
Phillips IR et al. (1985) A cytochrome P-450 gene family mapped to human chromosome 19. |
26. |
Nebert DW et al. (1987) P450 genes: structure, evolution, and regulation. |
27. |
Davis MB et al. (1986) Regional localization of a human cytochrome P-450 (CYP1) to chromosome 19q13.1-13.3. |
28. |
None (1987) Linkage between the loci for peptidase D and cytochrome P-450 (CYP1) on chromosome 19. |
29. |
Phillips IR et al. (1985) Isolation and sequence of a human cytochrome P-450 cDNA clone. |
30. |
Wainwright BJ et al. (1985) RFLP for a human cytochrome P-450 gene at 19q13.1-qter (HGM8 provisional designation CYPI). |
31. |
Fernandez-Salguero P et al. (1995) A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles. |
32. |
Nelson DR et al. () The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. |
33. |
Aida K et al. (1994) Lack of the steroid 15 alpha-hydroxylase gene (Cyp2a-4) in wild mouse strain Mus spretus: rapid evolution of the P450 gene superfamily. |
34. |
Nakajima M et al. (1996) Role of human cytochrome P4502A6 in C-oxidation of nicotine. |
35. |
Hadidi H et al. (1997) A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. |
36. |
Yokoi T et al. (1998) Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. |
37. |
None (1976) Coumarin-7-hydroxylase activity in microsomes from needle biopsies of normal and diseased human liver. |
38. |
Pianezza ML et al. (1998) Nicotine metabolism defect reduces smoking. |
39. |
Oscarson M et al. (1998) Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. |
40. |
Kleinbloesem CH et al. (1984) Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. |
41. |
Idle JR et al. (2000) Medical implications of HGP's sequence of chromosome 22. |
42. |
Nakamura K et al. (2002) CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability. |
43. |
Nelson DR et al. (2004) Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. |
44. |
Gasche Y et al. (2004) Codeine intoxication associated with ultrarapid CYP2D6 metabolism. |
45. |
Gaedigk A et al. (1991) Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism. |
46. |
Koren G et al. (2006) Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. |
47. |
Desmeules J et al. (1991) Impact of environmental and genetic factors on codeine analgesia. |
48. |
Gough AC et al. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. |
51. |
Chen X et al. (1995) The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. |
52. |
Johansson I et al. (1993) Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. |
53. |
Panserat S et al. (1994) DNA haplotype-dependent differences in the amino acid sequence of debrisoquine 4-hydroxylase (CYP2D6): evidence for two major allozymes in extensive metabolisers. |
54. |
Saxena R et al. (1994) Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. |
55. |
Broly F et al. (1995) A nonsense mutation in the cytochrome P450 CYP2D6 gene identified in a Caucasian with an enzyme deficiency. |
56. |
Steen VM et al. (1995) Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. |
57. |
Marez D et al. (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. |
59. |
Guengerich FP et al. (1986) Human-liver cytochromes P-450 involved in polymorphisms of drug oxidation. |
60. |
Gough SM et al. (2003) Refined physical map of the human PAX2/HOX11/NFKB2 cancer gene region at 10q24 and relocalization of the HPV6AI1 viral integration site to 14q13.3-q21.1. |
61. |
Tate SK et al. (2005) Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin. |
62. |
Kohn MH et al. (2000) A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans. |
63. |
et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. |
64. |
Aithal GP et al. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. |
65. |
Kidd RS et al. (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. |
66. |
Thum T et al. (2000) Gene expression in distinct regions of the heart. |
67. |
Aithal GP et al. (2000) Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. |
68. |
Xie HG et al. (2001) Molecular basis of ethnic differences in drug disposition and response. |
69. |
Leung AY et al. (2001) Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. |
70. |
Higashi MK et al. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. |
71. |
Williams PA et al. (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. |
72. |
Kirchheiner J et al. (2003) Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites. |
73. |
Fichtlscherer S et al. (2004) Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. |
74. |
King BP et al. (2004) Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. |
75. |
Sanderson S et al. (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. |
76. |
Li T et al. (2006) Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. |
77. |
Gray IC et al. (1995) A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24. |
78. |
Steward DJ et al. (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3. |
79. |
Caldwell MD et al. (2008) CYP4F2 genetic variant alters required warfarin dose. |
80. |
Yuan HY et al. (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. |
81. |
Lessard E et al. (1997) Role of CYP2D6 in the N-hydroxylation of procainamide. |
82. |
Lessard E et al. (1999) Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. |
83. |
Lindberg RL et al. (1992) Molecular characterization of the murine Coh locus: an amino acid difference at position 117 confers high and low coumarin 7-hydroxylase activity in P450coh. |
84. |
O'REILLY RA et al. (1964) HEREDITARY TRANSMISSION OF EXCEPTIONAL RESISTANCE TO COUMARIN ANTICOAGULANT DRUGS. THE FIRST REPORTED KINDRED. |
86. |
Rost S et al. (2004) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. |
88. |
Cooper GM et al. (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. |
89. |
Limdi NA et al. (2008) VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. |
90. |
Borgiani P et al. (2009) CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. |
91. |
Takeuchi F et al. (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. |
92. |
Nebert DW et al. () The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. |
93. |
Alving BM et al. (1985) Hereditary warfarin resistance. Investigation of a rare phenomenon. |
94. |
Vesell ES et al. (1968) Genetic control of dicumarol levels in man. |
95. |
None (1970) The second reported kindred with hereditary resistance to oral anticoagulant drugs. |
96. |
Pool JG et al. (1968) Warfarin resistance in the rat. |
97. |
Lewis RJ et al. (1967) Warfarin resistance. |
98. |
Greavses JH et al. (1967) Heritable resistance to warfarin in rats. |
99. |
Whitlon DS et al. (1978) Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. |
100. |
Tucker GT et al. (1977) Polymorphic hydroxylation of debrisoquine. |
101. |
Heim MH et al. (1992) Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. |
102. |
Heim M et al. (1990) Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. |
103. |
Kimura S et al. (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. |
104. |
Matsunaga E et al. (1989) The CYP2D gene subfamily: analysis of the molecular basis of the debrisoquine 4-hydroxylase deficiency in DA rats. |
105. |
Skoda RC et al. (1988) Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. |
106. |
Gonzalez FJ et al. (1988) Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. |
107. |
Gonzalez FJ et al. (1988) Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. |
108. |
Eichelbaum M et al. (1987) Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22. |
109. |
Gonzalez FJ et al. (1987) Debrisoquine 4-hydroxylase: characterization of a new P450 gene subfamily, regulation, chromosomal mapping, and molecular analysis of the DA rat polymorphism. |
110. |
Harmer D et al. (1986) The relationship between the acetylator and the sparteine hydroxylation polymorphisms. |
111. |
Eichelbaum M et al. (1986) The genetic polymorphism of sparteine metabolism. |
112. |
Nebert DW et al. (1987) The P450 gene superfamily: recommended nomenclature. |
113. |
Eichelbaum M et al. (1985) Inter-ethnic difference in sparteine oxidation among Ghanaians and Germans. |
114. |
Distlerath LM et al. (1984) Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme. |
115. |
Dahl ML et al. (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. |
116. |
Agúndez JA et al. (1995) Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. |
117. |
Mura C et al. (1993) DNA haplotype dependency of debrisoquine 4-hydroxylase (CYP2D6) expression among extensive metabolisers. |
119. |
Bertilsson L et al. (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. |
120. |
Gough AC et al. (1993) Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis. |
121. |
Daly AK et al. (1996) Nomenclature for human CYP2D6 alleles. |
122. |
Nelson DR et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. |
123. |
None (1997) Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? |
124. |
Sachse C et al. (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. |
125. |
McLellan RA et al. (1997) Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. |
126. |
Tyndale RF et al. (1997) Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. |
127. |
Mikus G et al. (1998) Relevance of deficient CYP2D6 in opiate dependence. |
128. |
Lundqvist E et al. (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. |
130. |
Tateishi T et al. (1999) Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. |
131. |
Brown MA et al. (2000) Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. |
132. |
Payami H et al. (2001) Parkinson's disease, CYP2D6 polymorphism, and age. |
133. |
Elbaz A et al. (2004) CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease. |
134. |
Deng Y et al. (2004) Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease. |
135. |
Liou YH et al. (2006) The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population. |
136. |
Pilotto A et al. (2009) Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease. |
137. |
Schroth W et al. (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. |
138. |
Sullivan-Klose TH et al. (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. |
139. |
None (2001) Racial differences in the response to drugs--pointers to genetic differences. |
140. |
Maekawa K et al. (2006) Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. |
141. |
Speed WC et al. (2009) Global variation in CYP2C8-CYP2C9 functional haplotypes. |
142. |
Ross KA et al. (2010) Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements. |
143. |
Shurin SB et al. (2008) Pharmacogenomics--ready for prime time? |